# BigHat Biosciences: Research, San Mateo, United States > BigHat Biosciences: BigHat Biosciences is a biotechnology company founded in 2019 and based in San Mateo, California. Based in San Mateo, United States. Source: https://millionrounds.com/startup/bighat-biosciences (Millionrounds; every figure on the page links to its filing or article) United States · [Research startup](https://millionrounds.com/companies) # BigHat Biosciences BigHat Biosciences is a biotechnology company founded in 2019 and based in San Mateo, California. Funding reported Last round: Series B Research San Mateo, United States Company summary - **Founded:** 2019 7 years old - **Team:** 96 51 to 200 people - **Funding reported:** $175M in dollars - **Last round:** Series B Jul 2022 How sure we are - ✓ **Listed** We know it exists and what it does - 2 **Funding reported** A company dataset reports a raise - 3 **Observed** A filing or a dated announcement confirms a round No round for BigHat Biosciences has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology) ## About BigHat Biosciences BigHat Biosciences is a biotechnology company founded in 2019 and based in San Mateo, California. The company focuses on designing safer and more effective antibody therapies using its proprietary MillinerTM platform, which integrates machine learning, synthetic biology, and automated high-speed wet-lab automation. BigHat aims to improve human health by simplifying the design of advanced antibody therapeutics for challenging diseases in oncology, inflammation, and immunology. As a Series B company, BigHat has raised over $100 million in funding, including a $75 million Series B round led by Section 32. The company has a pipeline of 10 therapeutic programs and collaborates with notable pharmaceutical partners such as AbbVie, Eli Lilly, Merck, and Amgen. With a team of approximately 80 to 112 employees, BigHat fosters a team-oriented and inclusive culture, emphasizing innovation in drug discovery and development. ## What company datasets say BigHat Biosciences raised Funding, as reported Reported in all **$175M** in dollars Rounds **4** Last round **Series B** Last round size **$75M** Last round date **Jul 2022** Investors listed **5** SEC Form D **$228M sold, 4 filings, last Apr 2025** ## Founders and team From BigHat Biosciences's own website: 1 founder, 34 on the team. **Peyton Greenside** CEO & Co-Founder - **Eddie Abrams** Chief Information Officer - **John Corbin** Chief Development Officer - **Liz Schwarzbach** Chief Business Officer - **Stefan Weigand** Chief Scientific Officer - **Brett Weinstein** VP, Finance - **Charbel Eid** VP, Platform - **Aaron Solomon** Associate Director, Computational Platform - **Amgen’ Golden Ticket** Partner - **Anisha Keshavan** Principal Data Scientist - **Annalisa Sharkey** Product Manager II - **Cameron Corday** Associate Scientist - **Crystal Humphries** Principal Data Scientist - **Dan Anderson** Senior Software Engineer II - **Danielle Barreras** Associate Scientist - **Eman Khan** Senior Research Associate - **Emma Scaff** Research Associate I - **Eva Boettcher** Associate Scientist - **Helena Fu** Associate Scientist And 16 more on the team. Advisers *Mark DePristo* *Stanley Lapidus* *Theresa Tribble* ## On 4 portfolio pages Investors who name them - [8VC](https://millionrounds.com/fund/8vc) - [Olima Ventures](https://millionrounds.com/fund/olima-ventures) - [Flucas Ventures](https://millionrounds.com/fund/flucas-ventures) - [Walker Street Capital](https://millionrounds.com/fund/walker-street-capital) Each firm lists BigHat Biosciences on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source. ## The company, in detail What they build Known for health care biotech high-throughput platforms biotech strategic partnerships biotechnology research therapeutic antibody engineering biotherapeutic design automation biologics development manufacturing multi-specific antibody engineering rapid antibody screening de novo antibody design antibody optimization algorithms data-driven drug discovery machine learning platform biotech funding ai-enabled biologics manufacturing Built with from their website DocuSign Amazon CloudFront Google Sheets Azure PlayFab Atlassian CallMiner Eureka TypeScript Flow AWS Cloud Development Kit QuickBooks +8 more YouTube Smartsheet Cloudflare DNS Google Workspace Django Zoom Meetings CloudFlare Electron - **Sector:** Research - **Industry code:** NAICS 541714, SIC 2834, 2836, 8731 - **Region:** California - **Revenue:** $26M a year, as listed ## Research in United States Startups like it - [**OpenAI** San Francisco · founded 2011 *Raised*](https://millionrounds.com/company/openai) - [**Retro Biosciences** Redwood City · founded 2021 *Raised*](https://millionrounds.com/company/retro-biosciences) - [**NewLimit** South San Francisco · founded 2022 *Raised*](https://millionrounds.com/company/newlimit) - [**Pathos** New York · founded 2022 *Raised*](https://millionrounds.com/company/pathos) - [**Colossal Biosciences** Dallas · founded 2021 *Raised*](https://millionrounds.com/company/colossal-biosciences) - [**Oratomic** South Pasadena *Raised*](https://millionrounds.com/company/oratomic) - [**Beeline Medicines** Stamford · founded 2025 *Raised*](https://millionrounds.com/company/beeline-medicines) - [**Element Biosciences** San Diego · founded 2017 *Raised*](https://millionrounds.com/company/element-biosciences) ## Is this your company? Add your raise, your deck and your story, and put BigHat Biosciences in front of investors. Or tell us what we have wrong. [List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)